Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans
- 1 May 1995
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 25 (5) , 467-479
- https://doi.org/10.1111/j.1365-2222.1995.tb01079.x
Abstract
Summary: To monitor endogenous production of cysteinyl‐containing leukotrienes, the end‐metabolite leukotriene E4 (LTE4) was analysed in urine. Results obtained with a sensitive enzyme immunoassay (EIA), performed on crude urine samples correlated well with data obtained from a previously reported radioimmunoassay. Enzyme immunoassay analysis of unextracted urine was justified by an excellent agreement between analyses in crude samples and measurements achieved after purification on solid phase extraction followed by separation on reversed‐phase high performance liquid chromatography. Moreover, LTE4 was stable in urine samples stored at ‐20°C, for months without the addition of preservatives. The stability of LTE4 in urine was not improved by addition of the antioxidant 4‐hydroxy‐TEMPO and pH adjustment to 9. As assessed by EIA analysis in crude urine samples, baseline values for urinary leukotriene E4 were not significantly different between atopic asthmatic subjects and non‐asthmatic individuals, and there was no diurnal variation in urinary excretion of LTE4 in healthy subjects. However, we confirmed earlier data on significantly higher basal levels of urinary LTE4 in aspirin‐intolerant asthmatics. In addition, a post‐challenge increase in urinary LTE4 levels was detected in association with allergeninduced airway obstruction in atopic asthmatics. The per cent increase in urinary LTE4 was similar, irrespective of whether the samples were purified or not prior to EIA. Thus, combined with random validation by high performance liquid chromatography, the strategy of direct EIA of serially diluted urine samples was found to be a good index of in vivo production of leukotrienes. This was further reinforced by the demonstration that pretreatment with the leukotriene biosynthesis inhibitor Bay × 1005 inhibited the post allergen‐challenge increase in urinary LTE4, as shown both with unpurilied and purified samples.Keywords
This publication has 39 references indexed in Scilit:
- The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmaticsEuropean Respiratory Journal, 1994
- Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthmaJournal of Allergy and Clinical Immunology, 1992
- Characteristics of formation and further metabolism of leukotrienes in the chopped human lungBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- Analysis of cysteinyl leukotrienes in human urine:enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome*European Journal of Clinical Investigation, 1989
- The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individualsBiochemical and Biophysical Research Communications, 1987
- Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological EffectsScience, 1987
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986
- In vivo metabolism of leukotriene C4 in man: Urinary excretion of leukotriene E4Biochemical and Biophysical Research Communications, 1985
- Generation of leukotrienes by purified human lung mast cells.Journal of Clinical Investigation, 1982
- Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response.Proceedings of the National Academy of Sciences, 1981